Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | PSEN1 | P49768 | 5/20 | 0.32 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.32 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.32 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.32 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2966941 | 1.00 | MAPK14 (0.43) | MAPK14MAPK13MAPK12MAPK11POLB | |
| SCHEMBL2965174 | 0.94 | MAPK14 (0.39) | MAPK14MAPK13MAPK12MAPK11POLB | |
| SCHEMBL2965613 | 0.93 | MAPK14 (0.40) | MAPK14MAPK13MAPK12MAPK11POLB | |
| SCHEMBL8318851 | 0.93 | MAPK14 (0.40) | MAPK14MAPK13MAPK12MAPK11POLB | |
| SCHEMBL8320609 | 0.93 | MAPK13 (0.39) | MAPK14MAPK13MAPK12MAPK11POLB | |
| SCHEMBL2954505 | 0.93 | MAPK13 (0.39) | MAPK14MAPK13MAPK12MAPK11POLB | |
| SCHEMBL8317823 | 0.91 | PSEN1 (0.39) | MAPK14MAPK13MAPK12MAPK11POLB | |
| SCHEMBL2966095 | 0.91 | PSEN1 (0.39) | MAPK14MAPK13MAPK12MAPK11POLB | |
| SCHEMBL8320857 | 0.84 | PSEN1 (0.39) | MAPK14MAPK13MAPK12MAPK11POLB | |
| SCHEMBL2958960 | 0.84 | PSEN1 (0.39) | MAPK14MAPK13MAPK12MAPK11POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2511267-A1 | 3-((N-ACYLATED AMINOACYL)AMINO)PYRAZOLES AS INHIBITORS OF BETA-AMYLOID PEPTIDE PRODUCTION USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals Inc. (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20100280066-A1 | ACYLATED AMINO ACID AMIDYL PYRAZOLES AND RELATED COMPOUNDS | TUNG JAY S | 2010-11-04 | — | — | US | disclosed |
| US-20100280066-A1 | ACYLATED AMINO ACID AMIDYL PYRAZOLES AND RELATED COMPOUNDS | TUNG JAY S | 2010-11-04 | — | — | US | disclosed |
| US-7759382-B2 | such as N-{5-[1-(4-chloro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-propionamide, used for inhibiting beta-amyloid peptide release and/or biosynthesis, inhibiting gamma-secretase activity, prevention and treatment of Alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759382-B2 | such as N-{5-[1-(4-chloro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-propionamide, used for inhibiting beta-amyloid peptide release and/or biosynthesis, inhibiting gamma-secretase activity, prevention and treatment of Alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2010-07-20 | — | — | US | disclosed |
| US-20070197624-A1 | Acylated amino acid amidyl pyrazoles and related compounds | ELAN PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070197624-A1 | Acylated amino acid amidyl pyrazoles and related compounds | ELAN PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| WO-2005009344-A2 | ACYLATED AMINO ACID AMIDYL PYRAZOLES AND RELATED COMPOUNDS | ELAN PHARMACEUTICALS, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280066-A1 | ACYLATED AMINO ACID AMIDYL PYRAZOLES AND RELATED COMPOUNDS | APP, BACE1, APH1A | MAPK14 1537/4885MAPK13 2162/4885MAPK12 2298/4885 |
| US-20070197624-A1 | Acylated amino acid amidyl pyrazoles and related compounds | APP, BACE1, APH1A | MAPK14 1537/4885MAPK13 2162/4885MAPK12 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.